1 / 12

Use of Azithromycin and Death from Cardiovascular Causes

Use of Azithromycin and Death from Cardiovascular Causes. Whitney Shirley University of Georgia Pharm.D . Candidate 2014. Azithromycin: Background Information. Macrolide antibiotic Treats Lower and upper respiratory infections Skin and soft-tissue infections Sexually transmitted diseases

emile
Télécharger la présentation

Use of Azithromycin and Death from Cardiovascular Causes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Use of Azithromycin and Death from Cardiovascular Causes Whitney Shirley University of Georgia Pharm.D. Candidate 2014

  2. Azithromycin: Background Information • Macrolide antibiotic • Treats • Lower and upper respiratory infections • Skin and soft-tissue infections • Sexually transmitted diseases • Adverse events • Increased risk of death from cardiovascular causes seen in patients who are at a high baseline risk

  3. Objectives • Investigate the potential pro-arrhythmic effect of Azithromycin • Rational: • Other macrolide antibiotics are known to prolong the QT interval • Primary outcome • Cardiovascular death • Secondary outcome • Death from other causes

  4. Methods • Inclusion Criteria • 18-64 years old • Denmark resident for the past 2 years • Exclusion Criteria • hospitalizations/antibiotic use within the past 30 days • No prescription filled within 1 year before the index date • Received another antibiotic on index date

  5. Methods • Prospective study • 1997-2010 • Azithromycin vs antibiotic use • N=2,204,100 • 1:1 ratio • Azithromycin vs Penicillin use • N=1,102,419 (azithromycin) • N=7,364,292 (Penicillin) • Current use: 1-5 days • Recent use: 6-10 days • Past use: 11-35 days

  6. Results • Primary outcomes • Significant increase in the risk of death from cardiovascular causes with current use of Azithromycin versus no antibiotic use • Rate ratio: 2.85 • 95% confidence interval 1.13 to 7.24 • NO increased risk of cardiovascular death was seen in Azithromycin use over Penicillin • Rate ratio: 0.93 • 95% confidence interval 0.56 to 1.55

  7. Results • Secondary outcomes • Azithromycin versus no antibiotic use • Rate ratio: 1.60 • 95% confidence interval 1.00 to 2.54 • Azithromycin versus Penicillin use • 46 deaths during current use of Azithromycin • Incidence rate: 3.1 per 1,000 person-years • 410 deaths during current use of Penicillin • Incidence rate: 4.1 per 1,000 person-years

  8. Results HenrikSvanström, M.Sc., Björn Pasternak, M.D., Ph.D., and Anders Hviid, Dr.Med.Sci. N Engl J Med 2013; 368:1704-1712 May2,2013 DOI: 10.1056/NEJMoa1300799

  9. Sensitivity Analysis HenrikSvanström, M.Sc., Björn Pasternak, M.D., Ph.D., and Anders Hviid, Dr.Med.Sci. N Engl J Med 2013; 368:1704-1712 May2,2013 DOI: 10.1056/NEJMoa1300799

  10. Conclusions • Significant increased risk of cardiovascular death was seen in Azithromycin use versus no antibiotic use, but was not seen when comparing Azithromycin use versus Penicillin use • The increased risk seen in the first group is contributed to the risk of death associated with acute infection rather than Azithromycin use • NO association between azithromycin use and increased risk of death from cardiovascular causes in young and middle-aged adults

  11. Seminarian’s Conclusions • Azithromycin is a safe and effective antibiotic when used in the general population • Caution should be taken when prescribing azithromycin in elderly patients or in those patients who have extensive health care problems

  12. References • Svanströmet al. Use of Azithromycin and Death from Cardiovascular Causese. N Engl J Med 2013; 368:1704-1712 May2,2013 DOI: 10.1056/NEJMoa1300799 • Ray et al. Azithromycin and the Risk of Cardiovascular Death. N Engl J Med 2012; 366:1881-1890May 17, 2012DOI: 10.1056/NEJMoa1003833

More Related